Highlight
- Low-dose colchicine (0.5 mg) shows a non-significant trend toward reducing major adverse cardiovascular events (MACE) in acute myocardial infarction (AMI) patients.
- Hospital readmission rates are significantly reduced by nearly 50% with colchicine treatment.
- Colchicine increases diarrhea risk but does not significantly affect mortality, myocardial infarction, stroke, or other gastrointestinal adverse events.
- Long-term clinical benefits and safety require further validation through extended follow-up studies.
Study Background and Disease Burden
Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. Persistent inflammation plays a critical role in atherosclerosis progression and post-AMI complications. Traditional therapies focus on reperfusion and secondary prevention, but residual inflammation poses an ongoing threat to cardiovascular health. Colchicine, a well-known anti-inflammatory agent, has attracted attention for its potential to modify cardiovascular risk by attenuating inflammatory processes implicated in plaque instability and thrombosis. However, its clinical impact at low dosages in the immediate AMI setting remains uncertain. Clarifying colchicine’s efficacy and safety in this population could shape adjunctive treatment strategies to improve outcomes.
Study Design
This updated meta-analysis systematically reviewed randomized controlled trials (RCTs) comparing a 0.5 mg dose of colchicine versus placebo in patients with AMI. The search encompassed PubMed, Scopus, Web of Science, and Cochrane Central databases from inception through January 2025. Ten RCTs encompassing 13,623 patients with follow-up periods ranging from 5 days to 36 months were included. The primary endpoint was incidence of major adverse cardiovascular events (MACE), a composite measure typically including cardiovascular death, myocardial infarction, and stroke. Secondary endpoints comprised individual MACE components, cardiovascular and non-cardiovascular mortality, atrial fibrillation (AF), hospital readmission rates, and gastrointestinal adverse effects such as diarrhea.
Key Findings and Results
Analysis revealed that low-dose colchicine was associated with a non-significant trend toward reducing MACE compared to placebo (relative risk [RR] 0.90; 95% confidence interval [CI], 0.80 to 1.01; p = 0.07). This suggests a possible modest benefit though not reaching conventional statistical significance. Heterogeneity across studies was minimal (I² = 0%), indicating consistent findings.
A notable significant finding was a 49% reduction in hospital readmission rates among colchicine-treated patients (odds ratio [OR] 0.51; 95% CI, 0.26 to 0.98; p = 0.04). This translates to a number needed to treat (NNT) of 25 to prevent one hospital readmission, a clinically meaningful effect given the burdens and costs associated with recurrent hospitalizations.
Regarding safety, colchicine increased the risk of diarrhea (RR 1.58; 95% CI, 1.06 to 2.36; p = 0.03), with a number needed to harm (NNH) of 50. Importantly, there were no significant differences between colchicine and placebo groups in all-cause mortality, cardiovascular mortality, recurrent myocardial infarction, stroke, or other gastrointestinal adverse events. The elevated diarrhea risk warrants attention but appears manageable given its relatively low incidence.
Expert Commentary
The observed trend toward reduced MACE supports the biological rationale of colchicine’s anti-inflammatory effects in stabilizing atherosclerotic plaques and preventing post-AMI complications. The significant reduction in hospital readmissions implies benefits in clinical stability and reduced recurrent events or decompensations that require inpatient care.
Nonetheless, the lack of statistical significance on MACE signals that larger-scale or longer-duration trials may be required to confirm efficacy conclusively. Variations in study design, patient populations, and follow-up length might influence outcomes and warrant consideration. The increased incidence of diarrhea is consistent with colchicine’s known gastrointestinal profile, emphasizing the importance of balancing risk-benefit ratios in clinical application.
Current guidelines acknowledge colchicine as a promising adjunct in secondary prevention after coronary events but refrain from broad endorsement until further evidence clarifies optimal dosing, timing, and patient selection. This meta-analysis informs ongoing discussions but does not yet define a new standard of care.
Conclusion
Low-dose colchicine (0.5 mg) administration in AMI patients is associated with a significant reduction in hospital readmission and a non-significant trend toward lower major adverse cardiovascular events. The increased risk of diarrhea is an important but manageable adverse effect. These findings underscore colchicine’s potential as an adjunctive anti-inflammatory therapy in the post-AMI setting but highlight the need for further large-scale, long-term trials to validate clinical benefits and safety profiles. Clinicians should weigh current evidence carefully and individualize treatment decisions pending more definitive guidance.
Funding and Clinical Trial Registration
No specific funding disclosures or clinical trial registrations were reported in the referenced meta-analysis publication.
References
Nazmy A, Sobhy A, Elshahat A, Atta K, Murad MR, Ibrahim M, El-Shirbiny H, Ibrahim RA, Sayed MS, Gomaa M, Shaban AY, Naeem M, Abdelaziz A. The effect of 0.5 mg dose of colchicine on clinical outcomes in patients with acute myocardial infarction: An updated meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2025 Nov;50(11):103169. doi: 10.1016/j.cpcardiol.2025.103169. Epub 2025 Sep 3. PMID: 40912343.
